专题：第八届中国国际进口博览会

　　11月7日消息，专注结构性心脏病领域的爱德华生命科学（以下简称“爱德华”）连续六年如约亮相中国国际进口博览会。此次参展，爱德华展现了覆盖瓣膜置换与修复的全线前沿产品及治疗方案，并带来PASCAL Precision经导管瓣膜修复系统中国香港上市后的进博首秀。同时，爱德华还与国药集团、上海医药等行业核心伙伴升级战略合作。

　　爱德华日本及亚太地区全球副总裁Wayne Markowitz表示，未来将继续秉持‘患者为先’的理念，依托进博会这一开放窗口，携手各方伙伴加速前沿科技的引进与临床转化。

　　爱德华大中华区高级副总裁兼总经理钟顺和表示，今年带来PASCAL Precision经导管瓣膜修复系统在中国香港上市后的进博首秀，标志着爱德华在经导管瓣膜修复领域的创新成果正加速向中国市场延伸。

　　PASCAL Precision经导管瓣膜修复系统为外科手术高风险的二尖瓣及三尖瓣反流患者提供了更加微创可靠的介入治疗新选择，据悉，该产品预计将于明年在中国内地获批。（刘丽丽）

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王珂

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.